02 January, 2003 |
| 11:18 |
Seasons Greetings |
A. D'Emanuele |
06 January, 2003 |
| 08:02 |
ANDA |
Vimal Patel |
10 January, 2003 |
| 14:50 |
BSE/TSE |
vim_1008 |
12 January, 2003 |
| 12:05 |
Re: BSE/TSE |
lt09 |
06 February, 2003 |
| 07:40 |
Named Patient supplies - EU |
Iftikhar Saiyed |
| 12:39 |
RE: Named Patient supplies - EU |
Lassoff, Peter |
| 17:57 |
RE: Named Patient supplies - EU |
Lassoff, Peter |
20 February, 2003 |
| 11:24 |
Brazilian Drug master file |
SUDESH MEHTA |
21 February, 2003 |
| 08:41 |
Incidence of extra peaks |
Dpcox |
| 16:03 |
RE: Incidence of extra peaks |
Bales, Frank |
| 18:55 |
Re: Incidence of extra peaks |
Dennis Fleming |
| 21:05 |
RE: Incidence of extra peaks |
Tom McMahon |
24 February, 2003 |
| 18:53 |
contents of Modules 4 & 5 of CTD |
Mona Gogia |
| 18:53 |
choice of reference product |
Mona Gogia |
| 21:58 |
RE: choice of reference product |
Lassoff, Peter |
25 February, 2003 |
| 12:52 |
IIG counterpart in Europe |
Mona Gogia |
| 12:53 |
Exhibit batch size requirements for non-oral generics |
Mona Gogia |
| 13:37 |
Re: Exhibit batch size requirements for non-oral generics |
Brian MATTHEWS |
| 13:38 |
Re: IIG counterpart in Europe |
Brian MATTHEWS |
26 February, 2003 |
| 07:57 |
CTD fromat for applications to US, EU & JAPAN |
Thirumurugan G (Regulatory Affairs) |
| 17:42 |
Re: CTD fromat for applications to US, EU & JAPAN |
lt09 |
27 February, 2003 |
| 06:33 |
Re: Exhibit batch size requirements for non-oral generics |
mona gogia |
| 06:33 |
Re: CTD fromat for applications to US, EU & JAPAN |
mona gogia |
| 14:44 |
Re: Exhibit batch size requirements for non-oral generics |
lt09 |
| 17:05 |
Clinical Trials Directive |
Bell, Sarah (SLH) |
28 February, 2003 |
| 08:05 |
schedule of FDA negative reports |
ERWINRF |
| 10:27 |
RE: schedule of FDA negative reports |
Rick Flora |
| 15:06 |
Re: schedule of FDA negative reports |
Dpcox |
03 March, 2003 |
| 12:41 |
Contents of module 4 & 5 |
Mona Gogia |
04 March, 2003 |
| 07:40 |
RE: Contents of module 4 & 5 |
Thirumurugan G (Regulatory Affairs) |
05 March, 2003 |
| 08:54 |
Residual solvents -Inhouse |
surit |
| 11:24 |
Re: Residual solvents -Inhouse |
Brian MATTHEWS |
| 13:12 |
Excipients |
Brian MATTHEWS |
06 March, 2003 |
| 07:46 |
Re: Excipients |
mona gogia |
| 09:01 |
Re: Excipients |
Theodor_Poettinger |
| 11:03 |
Re: Excipients |
Brian Matthews |
| 11:03 |
Re: Excipients |
Brian Matthews |
| 13:16 |
Reference product in BE for marketing authorisation |
Mona Gogia |
| 14:14 |
RE: Reference product in BE for marketing authorisation |
Lassoff, Peter |
| 14:14 |
Re: Reference product in BE for marketing authorisation |
Brian Matthews |
| 14:34 |
Re: Reference product in BE for marketing authorisation |
Bulcsu Herenyi |
07 March, 2003 |
| 18:29 |
RE: Reference product in BE for marketing authorisation |
mona gogia |
| 18:30 |
Re: Reference product in BE for marketing authorisation |
mona gogia |
| 18:30 |
IPEC GMP CERIFICATE |
surit |
08 March, 2003 |
| 13:15 |
Re: IPEC GMP CERIFICATE |
Brian MATTHEWS |
| 13:15 |
Re: Reference product in BE for marketing authorisation |
Brian MATTHEWS |
09 March, 2003 |
| 12:18 |
Re: IPEC GMP CERIFICATE |
HoroRL |
10 March, 2003 |
| 09:33 |
RE: Reference product in BE for marketing authorisation |
Lassoff, Peter |
| 13:50 |
European Pharmacopoeia |
Jeannette Westergaard |
| 15:20 |
Re: European Pharmacopoeia |
Brian MATTHEWS |
| 15:21 |
Re: European Pharmacopoeia |
sreedhare |
| 15:21 |
RE: European Pharmacopoeia |
Lassoff, Peter |
14 March, 2003 |
| 11:54 |
TSE/BSE |
anu sree |
| 12:56 |
RE: TSE/BSE |
Lassoff, Peter |
| 14:24 |
Re: TSE/BSE |
Brian MATTHEWS |
| 14:49 |
AW: TSE/BSE |
Giebel, Alexander {BD~Penzberg} |
| 15:30 |
Re: AW: TSE/BSE |
Bulcsu Herenyi |
| 16:06 |
RE: AW: TSE/BSE |
Lassoff, Peter |
| 16:07 |
Re: TSE/BSE |
Brian MATTHEWS |
| 18:38 |
Re: AW: TSE/BSE |
Brian MATTHEWS |
17 March, 2003 |
| 07:56 |
Common mfg facility for animal and human drug products |
monagogia |
| 09:25 |
Re: AW: TSE/BSE |
Bulcsu Herenyi |
| 12:57 |
Re: Common mfg facility for animal and human drug products |
marne.platt |
18 March, 2003 |
| 10:13 |
Re: Common mfg facility for animal and human drug products |
mona gogia |
| 16:03 |
Analytical methods validation |
"Cristina Blanco Fernández" |
| 16:21 |
RE: RegAffairs Digest - 18/03/03 |
Jeff Hirschorn |
| 20:20 |
Re: AW: TSE/BSE |
Brian MATTHEWS |
19 March, 2003 |
| 09:36 |
Re: AW: TSE/BSE |
Bulcsu Herenyi |
| 10:03 |
address |
prasanna sagar |
| 10:21 |
Re: AW: TSE/BSE |
Gordon.Urquhart |
| 17:08 |
Re: AW: TSE/BSE |
Brian Matthews |
| 17:09 |
Re: address |
Bulcsu Herenyi |
| 17:12 |
RE: address |
Vig, Indy |
| 17:12 |
Re: re: address |
Henrik Westerlind |
| 17:29 |
RE: address |
Lassoff, Peter |
| 17:29 |
RE: address |
Globepharm /MAnisfeld |
20 March, 2003 |
| 11:01 |
Exclusivity data |
prasanna sagar |
| 11:01 |
Biostudy |
prasanna sagar |
| 12:48 |
Re: Biostudy |
Brian MATTHEWS |
| 12:48 |
Re: Exclusivity data |
Brian MATTHEWS |
21 March, 2003 |
| 13:00 |
Re: Exclusivity data |
prasanna |
| 13:00 |
SD pork liver |
prasanna sagar |
| 13:00 |
INNOVATOR BRANDS |
prasanna sagar |
| 14:23 |
Re: Exclusivity data |
Brian MATTHEWS |
| 14:23 |
Re: INNOVATOR BRANDS |
Brian MATTHEWS |
| 14:25 |
Re: SD pork liver |
Brian MATTHEWS |
26 March, 2003 |
| 07:44 |
USDMF |
SUDESH |
| 09:33 |
EDMF and CEP |
Mona Gogia |
| 09:57 |
RE: USDMF |
Lassoff, Peter |
| 09:59 |
RE: EDMF and CEP |
Lassoff, Peter |
| 09:59 |
Re: EDMF and CEP |
Bulcsu Herenyi |
| 18:55 |
Barcodes Italy and Belgium |
stein |
27 March, 2003 |
| 08:35 |
overfill rate determination |
Lawrence |
| 09:43 |
RE: Barcodes Italy and Belgium |
Lassoff, Peter |
| 09:45 |
SPC |
prasanna |
| 21:57 |
RE: Barcodes Italy and Belgium |
stein |
| 23:32 |
Q on retesting |
marne.platt |
28 March, 2003 |
| 09:53 |
Re: Q on retesting |
Banie Boneschans |
| 11:02 |
RE: Barcodes Italy and Belgium |
Lassoff, Peter |
| 11:03 |
Toxicological Limits for Impurities. |
Srinivas Reddy |
